CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma
James L. Rubenstein,Valerie S. Wong,Cigall Kadoch,Hua Xin Gao,Ramon F. Barajas,Lingjing Chen,S. Andrew Josephson,Brian J. Scott,Vanja C. Douglas,Mekhala Maiti,Lawrence D. Kaplan,Patrick A. Treseler,Soonmee Cha,Jimmy Hwang,Paola Cinque,Jason G. Cyster,Clifford A. Lowell +16 more
Reads0
Chats0
TLDR
It is demonstrated for the first time that elevated CXCL13 concentration in cerebrospinal fluid (CSF) is prognostic and that CXC chemokine ligand and IL-10 mediate chemotaxis of lymphoma cells isolated from CNS lymphoma lesions.About:
This article is published in Blood.The article was published on 2013-06-06 and is currently open access. It has received 178 citations till now. The article focuses on the topics: Lymphoma & CXCL13.read more
Citations
More filters
Journal ArticleDOI
Multi-marker algorithms based on CXCL13, IL-10, sIL-2 receptor, and β2-microglobulin in cerebrospinal fluid to diagnose CNS lymphoma
Masahiro Maeyama,Takashi Sasayama,Kazuhiro Tanaka,Satoshi Nakamizo,Hirotomo Tanaka,Masamitsu Nishihara,Yuichi Fujita,Kenji Sekiguchi,Masaaki Kohta,Katsu Mizukawa,Takanori Hirose,Tomoo Itoh,Eiji Kohmura +12 more
TL;DR: A diagnostic algorithm that can avoid biopsy by combining these diagnostic biomarkers, which had excellent diagnostic performance and was a prognostic biomarker for CNS lymphoma patients, suggests that multi‐marker algorithms are important diagnostic tools for patients with CNS lymph cancer.
Journal ArticleDOI
Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas
Michalina Zajdel,Grzegorz Rymkiewicz,Maria Sromek,Maria Cieslikowska,Paweł Swoboda,Mariusz Kulinczak,Krzysztof Goryca,Zbigniew Bystydzienski,Katarzyna Blachnio,Beata Ostrowska,Anita Borysiuk,Agnieszka Druzd-Sitek,Jan Walewski,Magdalena Chechlinska,Jan Konrad Siwicki +14 more
TL;DR: Tissue MiR-155, miR-196b, mi R-9, mi-125b, and mi-R-let-7b expression profiles differentiate PCNSL from n-ML, and none of the examined microRNAs influenced overall survival of PC NSL patients.
Journal ArticleDOI
Endogenous adaptation to low oxygen modulates T-cell regulatory pathways in EAE.
TL;DR: In this paper, the authors define mechanisms by which adaptation to low oxygen functionally ameliorates the signs and symptoms of EAE and for the first time show that tissue hypoxia may fundamentally alter neurodegenerative disease.
Journal ArticleDOI
IL-10, IL-13, Eotaxin and IL-10/IL-6 ratio distinguish breast implant-associated anaplastic large-cell lymphoma from all types of benign late seromas
Arianna Di Napoli,Daniele Greco,Giorgia Scafetta,Francesca Ascenzi,Alessandro Gulino,Luigi Aurisicchio,Fabio Santanelli di Pompeo,Adriana Bonifacino,Enrico Giarnieri,John Morgan,Rita Mancini,Marshall E. Kadin +11 more
TL;DR: It is found that BI-ALCL is characterized by a Th2-type cytokine milieu associated with significant high levels of IL-10, IL-13 and Eotaxin which discriminate BI-alCL from all types of reactive seromas.
Book ChapterDOI
Cerebrospinal fluid biomarkers of malignancies located in the central nervous system.
TL;DR: This chapter provides a summary of the current state of affairs of the field of biomarkers of different types of CNS tumors, where techniques are rapidly progressing to assess these markers with increasing sensitivity and specificity and correlations with clinical parameters are being investigated.
References
More filters
Journal ArticleDOI
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.
Mark H. Zweig,Gregory Campbell +1 more
TL;DR: Receiver-operating characteristic (ROC) plots provide a pure index of accuracy by demonstrating the limits of a test's ability to discriminate between alternative states of health over the complete spectrum of operating conditions.
Journal ArticleDOI
Basic principles of ROC analysis
TL;DR: ROC analysis is shown to be related in a direct and natural way to cost/benefit analysis of diagnostic decision making and the concepts of "average diagnostic cost" and "average net benefit" are developed and used to identify the optimal compromise among various kinds of diagnostic error.
Journal ArticleDOI
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI
A Polycistronic MicroRNA Cluster, miR-17-92, Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation
Yoji Hayashita,Hirotaka Osada,Yoshio Tatematsu,Hideki Yamada,Kiyoshi Yanagisawa,Shuta Tomida,Yasushi Yatabe,Katsunobu Kawahara,Yoshitaka Sekido,Takashi Takahashi +9 more
TL;DR: Findings clearly suggest that marked overexpression of the miR-17-92 cluster with occasional gene amplification may play a role in the development of lung cancers, especially in their most aggressive form, small-cell lung cancer, and that the C13orf25 gene may well be serving as a vehicle in this regard.
Journal ArticleDOI
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more
TL;DR: An international group of experts meeting to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow to develop better therapies for patients.
Related Papers (5)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Andrés J.M. Ferreri,Michele Reni,Marco Foppoli,Maurizio Martelli,Gerasimus A. Pangalis,Maurizio Frezzato,Maria Giuseppina Cabras,Alberto Fabbri,Gaetano Corazzelli,Fiorella Ilariucci,Giuseppe Rossi,Riccardo Soffietti,Caterina Stelitano,Daniele Vallisa,Francesco Zaja,Lucia Zoppegno,Gian Marco Aondio,Giuseppe Avvisati,Monica Balzarotti,Alba A. Brandes,José Luis Crespo Fajardo,Henry L. Gomez,Attilio Guarini,Graziella Pinotti,Luigi Rigacci,Catrina Uhlmann,Piero Picozzi,Paolo Vezzulli,Maurilio Ponzoni,Emanuele Zucca,Federico Caligaris-Cappio,Franco Cavalli +31 more
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more